Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Abstract Background Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase often occur in infant-type hemispheric glioma (IHG) but also in other p...

Full description

Bibliographic Details
Published in:	Molecular Cancer
Main Authors:	Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura Hover, Jordan T. Roach, Kenneth Chun-Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Rankovic, Burgess B. Freeman, Jason Chiang, David T. W. Jones, Christopher L. Tinkle, Suzanne J. Baker
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Combination therapy Pediatric-type diffuse high-grade glioma Radiosensitization MET inhibition Preclinical trials Capmatinib
Online Access:	https://doi.org/10.1186/s12943-024-02027-6

Similar Items

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
by: Kei Kunimasa, et al.
Published: (2021-12-01)

HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies
by: Aref Zayed, et al.
Published: (2022-12-01)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
by: Daniel S Lefler, et al.
Published: (2022-12-01)

Review of real-world studies on capmatinib use in MET-mutated lung cancer
by: A. A. Kurylev, et al.
Published: (2025-04-01)

Mining and evaluation of adverse event signals for capmatinib based on the FAERS database
by: Xinnan Chen, et al.
Published: (2024-09-01)

Capmatinib suppresses LPS-induced interaction between HUVECs and THP-1 monocytes through suppression of inflammatory responses
by: Hyung Sub Park, et al.
Published: (2023-04-01)

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01)

Capmatinib targeted therapy in MET-fusion driven radiation induced glioma
by: Nolan Ford, et al.
Published: (2026-04-01)

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
by: Armando Santoro, et al.
Published: (2024-04-01)

Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
by: Caio Abner Leite, et al.
Published: (2023-10-01)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
by: Brazel D, et al.
Published: (2022-05-01)

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
by: Chien-Yu Lin, et al.
Published: (2022-08-01)

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
by: Siqi Xiang, et al.
Published: (2023-11-01)

A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis
by: Mohamed W. Attwa, et al.
Published: (2023-04-01)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
by: Fraser M, et al.
Published: (2023-11-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experience
by: R. Ben Dhiab, et al.
Published: (2025-06-01)

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression
by: Elisa Carouge, et al.
Published: (2025-02-01)

HGF/c-MET axis contributes to CLL cell survival by regulating multiple mechanisms making it a potential therapeutic target for CLL treatment
by: Shihao Liang, et al.
Published: (2025-05-01)

In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells
by: Ji Yeon Song, et al.
Published: (2024-11-01)

Rare Synchronous Lung Cancers in a Nonsmoker with Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition Alterations: A Case Report
by: Xavier Baer, et al.
Published: (2024-04-01)

Model‐based evaluation of image‐guided fractionated whole‐brain radiation therapy in pediatric diffuse intrinsic pontine glioma xenografts
by: Hillary R. Husband, et al.
Published: (2021-06-01)

A high-throughput quality control method for assessing the serial dilution performance of dose–response plates with acoustic ejection mass spectrometry
by: Mary Ashley Rimmer, et al.
Published: (2024-02-01)

Capmatinib-induced interstitial lung disease: A case report
by: Kinan El Husseini, et al.
Published: (2020-12-01)

Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution
by: Jaime L. Schneider, et al.
Published: (2023-11-01)

A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
by: Yiming Qi, et al.
Published: (2024-05-01)

Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation
by: Jinchao Zhao, et al.
Published: (2025-10-01)

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14–Mutant NSCLC
by: Paola Cravero, MD, et al.
Published: (2020-11-01)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
by: Monia Sisi, MD, et al.
Published: (2023-09-01)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
by: Shukui Qin, et al.
Published: (2019-12-01)

Corrigendum to “A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma”
Published: (2024-08-01)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Published: (2020-03-01)

Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct MET alterations revealed by tissue-based NGS testing
by: Wirote Lausoontornsiri, et al.
Published: (2025-07-01)

Health Problems Of Khumbu
by: J R McKinnon
Published: (2003-01-01)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
by: Yun-Tse Chou, et al.
Published: (2022-03-01)

YIMBY—Yes, In My BackYard!—The successful transition to a local online ecology field course
by: Laura McKinnon
Published: (2020-11-01)

Household size: an overlooked confounder when considering inequalities in food choice
by: Loretta McKinnon
Published: (2014-04-01)

Mesa Panel sobre Temor y temblor
by: Alastair McKinnon
Published: (2013-11-01)

The Impact of Aerobic Exercise on Mood Symptoms in Trauma-Exposed Young Adults: A Pilot Study
by: Allison L. Mizzi, et al.
Published: (2022-05-01)

A rare entity: Benign osteonecrosis of the temporal bone
by: Alexandra G. Whittaker, et al.
Published: (2022-08-01)